思春期早発症治療の世界市場レポート 2025年

思春期早発症治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.1％で24億5,000万米ドルに成長します。予測期間の成長は、小児ヘルスケアインフラの成長、個別化された治療アプローチ、心理社会的ウェルビーイングの重視、グローバルヘルスの取り組み、患者と親の教育プログラムに起因しています。予測期間における主な動向としては、GnRH（ゴナドトロピン放出ホルモン）アナログの研究、新規治療ターゲットの探索、個別化治療アプローチ、長時間作用型製剤の統合、患者のコンプライアンスとアドヒアランスの重視、補助療法の研究、遠隔モニタリングのための遠隔医療などが挙げられます。

ホルモン障害の罹患率の上昇により、思春期早発症治療市場の成長が今後促進されると予想されています。ホルモン障害は、ホルモンの産生と調節を担う内分泌系の機能障害や異常を伴います。これらの疾患は思春期早発症の原因となります。思春期早発症とは、特に視床下部-下垂体-性腺（HPG）軸に影響を及ぼす性ホルモンの調節の障害により、思春期が通常より早く始まる状態のことです。例えば、2023年5月、米国国立医学図書館は、米国では約1,300万人（人口の4.78％）が未診断の内分泌疾患を抱えていると報告しました。甲状腺疾患は最も一般的な疾患の一つであり、内分泌診療における症例の30～40％を占めています。さらに、代謝異常患者の半数近く（48.8％）が希少型であり、希少型代謝異常の一般的有病率は1万人当たり10.96人です。ホルモン障害の有病率の増加に伴い、思春期早発症の治療に対する需要が増加し、市場拡大の原動力になると予想されます。

思春期早発症の罹患率の上昇は、市場の成長に寄与すると予想されます。思春期早発症は、子供の思春期が早すぎることを特徴とする症状であり、身体は大人のような変化を早すぎる時期に受けています。思春期早発症の治療は、ホルモンバランスの乱れを調整し、心理的な健康をサポートし、成長パターンを正常化し、合併症を予防し、根本的な原因に対処することを目的としています。2023年3月、米国を拠点とする非営利のオープンアクセスジャーナル出版社PLOSが発表した報告書によると、中枢性思春期早発症（CPP）の年間発症率が大幅に増加していることが明らかになりました。男子では10万人当たり1.2人から100人へと83.3倍に、女子では10万人当たり88.9人から1414.7人へと15.9倍に増加しました。男児、女児ともに年間有病率は著しく急増し、思春期早発症の発生率が増加していることが明らかになり、市場における関連治療への需要を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の思春期早発症治療市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の思春期早発症治療市場：成長率分析
• 世界の思春期早発症治療市場の実績：規模と成長、2019～2024年
• 世界の思春期早発症治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の思春期早発症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の思春期早発症治療市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• リュープロレリン
• ヒストレリン
• トリプトレリン
• ナファレリン
• 世界の思春期早発症治療市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• その他
• 世界の思春期早発症治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児患者
• 成人
• その他
• 世界の思春期早発症治療市場：リュープロレリンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• リュープロレリン酢酸塩注射液
• リュープロレリンデポ投与
• 皮下投与用リュープロレリン
• 世界の思春期早発症治療市場：ヒストレリンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ヒストレリン酢酸インプラント
• ヒストレリンデポ注射剤
• 皮下投与用ヒストレリン
• 世界の思春期早発症治療市場：トリプトレリンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• トリプトレリン酢酸塩注射液
• トリプトレリン持続性デポ注射剤
• 皮下インプラント用トリプトレリン
• 世界の思春期早発症治療市場：ナファレリンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ナファレリン酢酸塩点鼻薬
• 注射剤投与用ナファレリン

第7章 地域別・国別分析

• 世界の思春期早発症治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の思春期早発症治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 思春期早発症治療市場：競合情勢
• 思春期早発症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Glenmark Pharmaceuticals Ltd.
• Sun Pharmaceutical Industries Ltd.
• Prime Therapeutics LLC
• Ipsen Ltd.
• Ferring Pharmaceuticals Private Limited
• Endo Pharmaceuticals Inc.
• Livzon Pharmaceutical Group Inc.
• Salvavidas Pharmaceutical Pvt. Ltd.
• Actiza Pharmaceutical Private Limited
• Biocon Limited
• Mallinckrodt plc
• Arbor Pharmaceuticals LLC
• Genentech Inc.
• Tolmar Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 思春期早発症治療市場2029：新たな機会を提供する国
• 思春期早発症治療市場2029：新たな機会を提供するセグメント
• 思春期早発症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Precocious puberty treatment involves medical interventions and therapies designed to manage and address the early onset of puberty in children. The primary goal of treatment is to slow down or halt the progression of puberty, mitigate the impact on the child's growth potential, and address any underlying causes or associated health concerns.

The main drug classes utilized in precocious puberty treatment include leuprorelin, histrelin, triptorelin, and nafarelin. Leuprorelin, also known as leuprolide acetate, is a synthetic medication employed in the fields of reproductive medicine and endocrinology. It belongs to the class of drugs known as gonadotropin-releasing hormone (GnRH) agonists. These drugs find applications in various settings, including hospitals, clinics, and other healthcare facilities, and can be administered to pediatric patients, adults, and individuals in need of such treatments.

The precocious puberty treatment market research report is one of a series of new reports from The Business Research Company that provides precocious puberty treatment market statistics, including precocious puberty treatment industry global market size, regional shares, competitors with a precocious puberty treatment market share, detailed precocious puberty treatment market segments, market trends and opportunities, and any further data you may need to thrive in the precocious puberty treatment industry. This precocious puberty treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The precocious puberty treatment market size has grown strongly in recent years. It will grow from $1.71 billion in 2024 to $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased incidence of precocious puberty, rise in awareness and early diagnosis, patient and parental concerns, collaborative efforts in pediatric healthcare, pediatric endocrinologist advocacy.

The precocious puberty treatment market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing pediatric healthcare infrastructure, individualized treatment approaches, focus on psychosocial well-being, global health initiatives, patient and parental education programs. Major trends in the forecast period include advancements in GnRH (Gonadotropin-releasing hormone) analogues, exploration of novel therapeutic targets, personalized treatment approaches, integration of long-acting formulations, focus on patient compliance and adherence, research on adjunct therapies, telemedicine for remote monitoring.

The increasing prevalence of hormonal disorders is expected to drive the growth of the precocious The rising prevalence of hormonal disorders is expected to propel the growth of the precocious puberty treatment market going forward. Hormonal disorders involve dysfunction or abnormalities in the endocrine system, which is responsible for producing and regulating hormones. These disorders can cause precocious puberty, a condition where puberty begins earlier than usual due to disruptions in the regulation of sex hormones, particularly affecting the hypothalamic-pituitary-gonadal (HPG) axis. For example, in May 2023, the National Library of Medicine reported that approximately 13 million people in the U.S. (4.78% of the population) have undiagnosed endocrine disorders. Thyroid disease is among the most common, accounting for 30-40% of cases in endocrine practices. Additionally, nearly half (48.8%) of patients with metabolic disorders have rare types, with a general prevalence of rare metabolic disorders at 10.96 per 10,000 individuals. As the prevalence of hormonal disorders increases, the demand for treatments for precocious puberty is expected to grow, thereby driving the expansion of the market.

The rising incidence of precocious puberty cases is expected to contribute to the market's growth. Precocious puberty is a condition characterized by the premature onset of puberty in children, with their bodies undergoing adult-such as changes too early. Treatment for precocious puberty aims to regulate hormonal imbalances, support psychological well-being, normalize growth patterns, prevent complications, and address underlying causes. A March 2023 report shared by PLOS, a U.S.-based nonprofit publisher of open-access journals in science, revealed a significant increase in the annual incidence of central precocious puberty (CPP). The incidence rose by 83.3 times in boys, from 1.2 to 100 per 100,000, and 15.9 times in girls, from 88.9 to 1414.7 per 100,000. The annual prevalence in both boys and girls surged significantly, underscoring the growing incidence of precocious puberty cases and driving the demand for related treatments in the market.

Major companies in the precocious puberty treatment market are concentrating on obtaining drug approvals, such as leuprolide acetate injection, to drive organizational growth in the market. The increasing number of drug approvals for precocious puberty treatment, such as leuprolide acetate injection, provides new therapeutic options. For instance, in November 2022, Amneal Pharmaceuticals Inc., a U.S.-based pharmaceutical company, received abbreviated new drug application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for leuprolide acetate injection. Leuprolide acetate is a synthetic form of gonadotropin-releasing hormone (GnRH) used to delay sexual development, such as the growth of breasts or testicles and the onset of menstruation.

In June 2022, Eversana Life Science Services LLC, a U.S.-based life sciences company, partnered with Accord BioPharma to support the launch of CAMCEVI for treating advanced prostate cancer in adults in the U.S. CAMCEVI (leuprolide mesylate) is also used to treat central precocious puberty. It is a synthetic hormone similar to a natural hormone produced in the brain, addressing various medical problems, including central precocious puberty. CAMCEVI is the first-ever sterile leuprolide ready-to-inject formulation for subcutaneous injection, delivered in a pre-filled syringe without the need for mixing. Accord BioPharma is a U.S.-based pharmaceutical company focused on developing and marketing treatments for various conditions, including central precocious puberty.

Major companies operating in the precocious puberty treatment market report are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Prime Therapeutics LLC, Ipsen Ltd., Ferring Pharmaceuticals Private Limited, Endo Pharmaceuticals Inc., Livzon Pharmaceutical Group Inc., Salvavidas Pharmaceutical Pvt. Ltd., Actiza Pharmaceutical Private Limited, Biocon Limited, Mallinckrodt PLC, Arbor Pharmaceuticals LLC, Genentech Inc., Tolmar Pharmaceuticals Inc., Debiopharm Group, Emcure Pharmaceuticals Ltd., Cadila Pharmaceuticals Limited, Sandoz International GmbH, Banner Life Sciences LLC, Foresee Pharmaceuticals Co. Ltd., Verity Pharmaceuticals Inc.

North America was the largest region in the precocious puberty treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precocious puberty treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the Precocious Puberty Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The precocious puberty treatment market consists of revenues earned by entities by providing services such as medical evaluation, hormone therapy, monitoring and follow-up, psychological and emotional support, nutritional guidance, parent and caregiver education, and social and school support. The market value includes the value of related goods sold by the service provider or included within the service offering. The precocious puberty treatment market also includes sales of gonadotropin hormone-releasing hormone (GnRH), triptorelin, and leuprolide acetate. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Precocious Puberty Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on precocious puberty treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for precocious puberty treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The precocious puberty treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Leuprorelin; Histrelin; Triptorelin; Nafarelin
• 2) By Application: Hospitals; Clinics; Other Applications
• 3) By End-User: Pediatric Patients; Adults; Other End-Users
• Subsegments:
• 1) By Leuprorelin: Leuprorelin Acetate Injection; Leuprorelin For Depot Administration; Leuprorelin For Subcutaneous Administration
• 2) By Histrelin: Histrelin Acetate Implant; Histrelin For Depot Injection; Histrelin For Subcutaneous Administration
• 3) By Triptorelin: Triptorelin Acetate Injection; Triptorelin For Long-Acting Depot Injection; Triptorelin For Subcutaneous Implantation
• 4) By Nafarelin: Nafarelin Acetate Nasal Spray; Nafarelin For Injectable Administration
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; AstraZeneca plc; Abbott Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Precocious Puberty Treatment Market Characteristics

3. Precocious Puberty Treatment Market Trends And Strategies

4. Precocious Puberty Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Precocious Puberty Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Precocious Puberty Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Precocious Puberty Treatment Market Growth Rate Analysis
• 5.4. Global Precocious Puberty Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Precocious Puberty Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Precocious Puberty Treatment Total Addressable Market (TAM)

6. Precocious Puberty Treatment Market Segmentation

• 6.1. Global Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leuprorelin
• Histrelin
• Triptorelin
• Nafarelin
• 6.2. Global Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other Applications
• 6.3. Global Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Patients
• Adults
• Other End-Users
• 6.4. Global Precocious Puberty Treatment Market, Sub-Segmentation Of Leuprorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Leuprorelin Acetate Injection
• Leuprorelin For Depot Administration
• Leuprorelin For Subcutaneous Administration
• 6.5. Global Precocious Puberty Treatment Market, Sub-Segmentation Of Histrelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Histrelin Acetate Implant
• Histrelin For Depot Injection
• Histrelin For Subcutaneous Administration
• 6.6. Global Precocious Puberty Treatment Market, Sub-Segmentation Of Triptorelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triptorelin Acetate Injection
• Triptorelin For Long-Acting Depot Injection
• Triptorelin For Subcutaneous Implantation
• 6.7. Global Precocious Puberty Treatment Market, Sub-Segmentation Of Nafarelin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nafarelin Acetate Nasal Spray
• Nafarelin For Injectable Administration

7. Precocious Puberty Treatment Market Regional And Country Analysis

• 7.1. Global Precocious Puberty Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Precocious Puberty Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Precocious Puberty Treatment Market

• 8.1. Asia-Pacific Precocious Puberty Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Precocious Puberty Treatment Market

• 9.1. China Precocious Puberty Treatment Market Overview
• 9.2. China Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Precocious Puberty Treatment Market

• 10.1. India Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Precocious Puberty Treatment Market

• 11.1. Japan Precocious Puberty Treatment Market Overview
• 11.2. Japan Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Precocious Puberty Treatment Market

• 12.1. Australia Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Precocious Puberty Treatment Market

• 13.1. Indonesia Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Precocious Puberty Treatment Market

• 14.1. South Korea Precocious Puberty Treatment Market Overview
• 14.2. South Korea Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Precocious Puberty Treatment Market

• 15.1. Western Europe Precocious Puberty Treatment Market Overview
• 15.2. Western Europe Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Precocious Puberty Treatment Market

• 16.1. UK Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Precocious Puberty Treatment Market

• 17.1. Germany Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Precocious Puberty Treatment Market

• 18.1. France Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Precocious Puberty Treatment Market

• 19.1. Italy Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Precocious Puberty Treatment Market

• 20.1. Spain Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Precocious Puberty Treatment Market

• 21.1. Eastern Europe Precocious Puberty Treatment Market Overview
• 21.2. Eastern Europe Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Precocious Puberty Treatment Market

• 22.1. Russia Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Precocious Puberty Treatment Market

• 23.1. North America Precocious Puberty Treatment Market Overview
• 23.2. North America Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Precocious Puberty Treatment Market

• 24.1. USA Precocious Puberty Treatment Market Overview
• 24.2. USA Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Precocious Puberty Treatment Market

• 25.1. Canada Precocious Puberty Treatment Market Overview
• 25.2. Canada Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Precocious Puberty Treatment Market

• 26.1. South America Precocious Puberty Treatment Market Overview
• 26.2. South America Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Precocious Puberty Treatment Market

• 27.1. Brazil Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Precocious Puberty Treatment Market

• 28.1. Middle East Precocious Puberty Treatment Market Overview
• 28.2. Middle East Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Precocious Puberty Treatment Market

• 29.1. Africa Precocious Puberty Treatment Market Overview
• 29.2. Africa Precocious Puberty Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Precocious Puberty Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Precocious Puberty Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Precocious Puberty Treatment Market Competitive Landscape And Company Profiles

• 30.1. Precocious Puberty Treatment Market Competitive Landscape
• 30.2. Precocious Puberty Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Precocious Puberty Treatment Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Glenmark Pharmaceuticals Ltd.
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Prime Therapeutics LLC
• 31.5. Ipsen Ltd.
• 31.6. Ferring Pharmaceuticals Private Limited
• 31.7. Endo Pharmaceuticals Inc.
• 31.8. Livzon Pharmaceutical Group Inc.
• 31.9. Salvavidas Pharmaceutical Pvt. Ltd.
• 31.10. Actiza Pharmaceutical Private Limited
• 31.11. Biocon Limited
• 31.12. Mallinckrodt plc
• 31.13. Arbor Pharmaceuticals LLC
• 31.14. Genentech Inc.
• 31.15. Tolmar Pharmaceuticals Inc.

32. Global Precocious Puberty Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Precocious Puberty Treatment Market

34. Recent Developments In The Precocious Puberty Treatment Market

35. Precocious Puberty Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Precocious Puberty Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Precocious Puberty Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Precocious Puberty Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer